"DEA Rescheduling Rumors Propel Cannabis ETF to 8% Gain"
TL;DR Summary
The AdvisorShares Pure US Cannabis ETF (MSOS) has surged over 8% amid rumors of the DEA potentially rescheduling cannabis to Schedule III, with renowned hedge fund manager Doug Kass fueling speculation. Despite recent rough performance for multi-state operators in the cannabis industry, the overall performance of cannabis stocks remains relatively better than other sectors. The upcoming Benzinga Cannabis Capital Conference in Florida is set to address these developments and provide a platform for networking and learning within the cannabis industry.
- Cannabis ETF Gains Momentum, Rising Over 8% As DEA Rescheduling Rumors Intensify (UPDATED) - AdvisorShare Benzinga
- Cannabis Stocks Jump as Government Pushes DEA to Reclassify Drug - TipRanks.com TipRanks
- Top Biden Health Official Defends Marijuana Rescheduling Recommendation Against Criticism From GOP Senator Marijuana Moment
- DEA Officials Reportedly At Odds With Biden Admin Over Marijuana Rescheduling Push Marijuana Moment
- DEA Vs. White House: Agency Pushes Back On Medical Benefits Of Cannabis, Weed Stocks Wobble - Green Thumb Benzinga
Reading Insights
Total Reads
0
Unique Readers
10
Time Saved
2 min
vs 3 min read
Condensed
83%
462 → 80 words
Want the full story? Read the original article
Read on Benzinga